Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Methylation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    157 result(s) found for: Methylation. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2017-002097-38 Sponsor Protocol Number: ABR62020 Start Date*: 2018-06-05
    Sponsor Name:University Medical Centre Utrecht
    Full Title: SAMe as an epigenetic treatment of depression in people with childhood trauma, a double blind placebo-controlled trial
    Medical condition: Depressive episode in people with childhood trauma
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005086-40 Sponsor Protocol Number: J1214 Start Date*: 2014-05-21
    Sponsor Name:Sidney kimmel Comprehensive Cancer Center at Johns Hopkins
    Full Title: A multi-institutional open label, trial evaluating the efficacy of Gemcitabine and Docetaxel in patients with relapsed or refractory metastatic colorectal adenocarcinoma with methylated CHFR and/or...
    Medical condition: relapsed or refractory metastatic colorectal adenocarcinoma with methylation of CHFR and/or microsatellite instability
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001407-23 Sponsor Protocol Number: GEICAM/2015-06 Start Date*: 2017-01-05
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: A Phase II Clinical Trial to analyse Olaparib Response in patients with BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETA-Breast study).
    Medical condition: Patients with advanced triple negative breast cancer (TNBC) with BRCA1 and/or BRCA2 promoter methylation assessed in DNA from metastatic lesions and absence of BRCA1 and 2 germline mutations.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-000149-53 Sponsor Protocol Number: D-STAPH Start Date*: 2014-05-06
    Sponsor Name:Karolinska University Hospital, Huddinge
    Full Title: ’D-STAPH’ Vitamin D supplementation to persistent carriers of MRSA – A double blind, randomised controlled trial
    Medical condition: Persistent MRSA carriers
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002542-33 Sponsor Protocol Number: ZYN2-CL-033 Start Date*: 2022-02-22
    Sponsor Name:Zynerba Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults with Fragile X Syndro...
    Medical condition: Fragile X syndrome (FXS) is a rare genetic disorder caused by the deficiency or absence of Fragile X Messenger Ribonucleoprotein 1 (FMRP), an RNA-binding protein and the gene product of the FMR1 ge...
    Disease: Version SOC Term Classification Code Term Level
    20.1 10010331 - Congenital, familial and genetic disorders 10017324 Fragile X syndrome PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000155-41 Sponsor Protocol Number: 1 Start Date*: 2019-01-10
    Sponsor Name:Department of Medical and Clinical Genetics, University of Helsinki
    Full Title: The effect of vitamin C on the gene methylation load in patients with TET2 mutations
    Medical condition: germline TET-2 gene mutation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-001060-38 Sponsor Protocol Number: DECO Start Date*: 2013-05-28
    Sponsor Name:Academic Medical center
    Full Title: Pre-operative Decitabine in colon cancer: a proof of principal study
    Medical condition: colon cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-015077-12 Sponsor Protocol Number: rrk3681 Start Date*: 2009-11-23
    Sponsor Name:University Hospital Birmingham NHS Foundation Trust
    Full Title: The use of corticosteroids (Budenofalk) as a chemopreventative agent in ulcerative colitis associated neoplasia
    Medical condition: chronic ulcerative colitis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023584-17 Sponsor Protocol Number: RAS-AZIC Start Date*: 2012-08-31
    Sponsor Name:Universität Leipzig
    Full Title: Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicent...
    Medical condition: acute myeloid leukeamia
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003184-62 Sponsor Protocol Number: J1369 Start Date*: 2014-04-23
    Sponsor Name:Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Full Title: A phase I study of SGI-110 combined with irinotecan followed by a randomized phase II study of SGI-110 combined with irinotecan versus regorafenib in previously treated metastatic colorectal cancer...
    Medical condition: Previously treated metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000689-30 Sponsor Protocol Number: Pem-NSCLC Start Date*: 2018-08-02
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie
    Full Title: Expression/DNA methylation of cancer testis antigens may predict response to pembrolizumab in pretreated NSCLC patients
    Medical condition: untreated patients with adenocarcinoma of the lung of advanced stage
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006224-40 Sponsor Protocol Number: AxGD Start Date*: Information not available in EudraCT
    Sponsor Name:Instytut ,,Pomnik-Centrum Zdrowia Dziecka"
    Full Title: Evaluation of the safety and efficacy of ambroxol (ABX) use in Polish patients with Gaucher disease, presenting neuronopathic type (GD type III, GD3) resulting from homozygous c.1448T>C mutation (p...
    Medical condition: Gaucher disease
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-003296-60 Sponsor Protocol Number: Oxidise Start Date*: 2018-04-09
    Sponsor Name:University Hospital Tuebingen
    Full Title: Empagliflozin effect on glucose toxicity in type 2 diabetes patients - a randomized, open-label, controlled, parallel group, exploratory study
    Medical condition: Patients with T2DM aged 40 to 70 years (including)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003977-24 Sponsor Protocol Number: SGI-110-03 Start Date*: 2014-03-20
    Sponsor Name:Astex Pharmaceuticals Inc
    Full Title: A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment with Sorafenib
    Medical condition: Advanced Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-004091-35 Sponsor Protocol Number: EMC-NET1 Start Date*: 2019-04-19
    Sponsor Name:Erasmus University Medical Center
    Full Title: Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients
    Medical condition: Neuroendocrine tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052399 Neuroendocrine tumour PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077559 Gastroenteropancreatic neuroendocrine tumour disease PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10078174 Neuroendocrine tumour of the lung PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-006151-20 Sponsor Protocol Number: D1449L00029 Start Date*: 2006-08-29
    Sponsor Name:University of Erlangen-Nuremberg
    Full Title: Quetiapine and the dopaminergic epigenetic control – a pilot study
    Medical condition: Patients suffering from schizophrenia (ICD10: F20.x) Healthy controls
    Disease: Version SOC Term Classification Code Term Level
    8.1 10039628 Schizophrenia and other psychotic disorders HLGT
    Population Age: Adults Gender: Male
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002267-25 Sponsor Protocol Number: SEOTP-2018 Start Date*: 2018-07-18
    Sponsor Name:Fakultní nemocnice Brno
    Full Title: SAFETY AND EFFICACY OF OLANZAPINE TREATMENT IN PSYCHOSIS: EFFECT OF GENETIC AND EPIGENETIC FACTORS – COVARIATES OF TREATMENT RESPONSE
    Medical condition: Psychoses
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000281-21 Sponsor Protocol Number: H6Q-MC-S039 Start Date*: 2007-09-05
    Sponsor Name:Eli Lilly and Company
    Full Title: Enzastaurin (LY317615) Before and Concomitant with Radiation Therapy, Followed by Enzastaurin Maintenance Therapy in Patients with Newly Diagnosed Glioblastoma without Methylation of the Promoter G...
    Medical condition: primary glioma without methylation of the promoter gene of MGMT enzyme
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018336 Glioblastoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003150-25 Sponsor Protocol Number: IRST162.09 Start Date*: 2015-01-21
    Sponsor Name:IRCCS ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
    Full Title: Phase II Trial of Temozolomide in Patients affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer with MGMT methylation. GOPAV03
    Medical condition: Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    17.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-006871-60 Sponsor Protocol Number: DIRECTOR Start Date*: 2009-06-23
    Sponsor Name:University Hospital Heidelberg, Ruprechts-Karl-University Heidelberg
    Full Title: Dose-intensified Rechallenge with Temozolomide, One Week on One Week Off versus Three Weeks on One Week Off in Patients with Progressive or Recurrent Glioblastoma
    Medical condition: progressive or recurrent glioblastoma after first surgery for glioblastoma and after completion of radiotherapy
    Disease: Version SOC Term Classification Code Term Level
    9.1 10018337 Glioblastoma multiforme LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:09:27 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA